Skip to content
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,441–1,450 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1441

    Medicine slug
    tacrolimus
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    44
    Source count
    40
    Agreement rate
    0.95
    Recorded readings
    1. 17±10%

      Numeric value
      17
      Unit
      %
      Source records
      38

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 38 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61dee012-43af-0e9a-3843-9b9b91e022c4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e0584d-16d2-442b-86ce-e5e65239db0c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:759cf905-7406-4d1b-a1a8-10068cb11f04 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed7d1495-3585-409d-94f1-b3d2469d222c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f667de1-9dfa-4bd6-8ba0-15ee2d78873b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10ceb3bc-11cc-13e4-e063-6394a90acce4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d03943-0655-44f6-b494-57bd1e336a34 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f21115e2-1d02-4bce-9c13-bf593a52a12f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd447ffa-9196-4c3c-accf-5adf29b84665 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f742224-618e-4f4c-bdec-7693be99c697 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3519febc-c9df-4559-b07a-92f8b0c7e770 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd9fea26-0236-d437-c7df-4b7636210875 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27154d3a-eec5-4000-a4ff-bfbfe27eb806 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:450c3e32-6d91-4508-b064-49b293e86cec (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45af3eda-caaa-4478-9372-95aa65adc9b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55467f4b-8437-43a3-b6d9-1bc2a13b4c11 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e8bc65e-8048-4073-8e45-570330603000 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:823b11cb-d873-4017-a861-d22d2c5a8a49 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34ec4989-6933-4237-ae1e-50a0cb90a2fe (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b310c6b-e035-4e44-9573-4001d58b2ad5 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0addf3f5-9bd5-4ef3-8c7f-52be20c16cf9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:393cd10e-133c-4d6b-b024-270eb82edbb3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca08d4aa-3de2-4a9d-9554-6288e5d36f29 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of Tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54fcc518-21d9-44a8-9e2c-87ebc2b3e2e6 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46ac55cf-d85e-4c34-bb33-f49e078c4a03 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e55495-10cc-4f6e-b866-1e7d6e45888b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:213f6047-f897-48a7-b78a-45d7124f2f16 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651bd506-96b0-43e5-a4dd-db03bf9154c9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e898ee90-faae-42a8-b652-be1c8730d856 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:976f1b69-dd96-4815-b11b-839ce1c45633 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dc347e3-9bfd-4910-adb5-24e979208345 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b89e8a4-9f11-42e3-8e79-fe617e7c461f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d1c12a-bf4b-4467-93a0-ee8b892abea9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4caa20af-45a8-4365-9f06-1568afae61b1 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23b7b4d7-1431-e9f2-43ba-eabd169dc2dd (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d502961-e9c0-4611-92bf-ce742a7b962c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:875f4962-557e-4e12-ad7b-cb5fb6f2a65f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant patients (N = 26), 22 ± 6% in adult liver transplant patients (N = 17), 23 ± 9% in adult heart transplant patients (N = 11) and 18 ± 5% in healthy volunteers (N = 16).
    2. 12 ± 4.5%

      Numeric value
      12
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The mean (± SD) absolute oral bioavailability (F) in African-Americans (12 ± 4.5%) and Latino-Americans (14 ± 7.4%) was lower than in Caucasians (19 ± 5.8%).
    3. 50%

      Numeric value
      50
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de2315b0-6344-43ac-9aea-3e3b68d828e7 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        In healthy subjects, the oral bioavailability of ENVARSUS XR was approximately 50% higher as compared with both tacrolimus immediate-release and extended-release capsule formulations at steady state.
  2. Projected row 1442

    Medicine slug
    tacrolimus
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    44
    Source count
    44
    Agreement rate
    0.954545
    Recorded readings
    1. 48.1±15.9 hours

      Numeric value
      48.1
      Unit
      hours
      Source records
      42

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 42 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61dee012-43af-0e9a-3843-9b9b91e022c4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e0584d-16d2-442b-86ce-e5e65239db0c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:759cf905-7406-4d1b-a1a8-10068cb11f04 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed7d1495-3585-409d-94f1-b3d2469d222c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f667de1-9dfa-4bd6-8ba0-15ee2d78873b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10ceb3bc-11cc-13e4-e063-6394a90acce4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d03943-0655-44f6-b494-57bd1e336a34 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f21115e2-1d02-4bce-9c13-bf593a52a12f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd447ffa-9196-4c3c-accf-5adf29b84665 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f742224-618e-4f4c-bdec-7693be99c697 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3519febc-c9df-4559-b07a-92f8b0c7e770 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd9fea26-0236-d437-c7df-4b7636210875 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bf44a84-14fd-4f80-ad8a-99b1431d631f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27154d3a-eec5-4000-a4ff-bfbfe27eb806 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e6817a-9b1e-4f0f-e053-2a91aa0a3d15 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:450c3e32-6d91-4508-b064-49b293e86cec (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45af3eda-caaa-4478-9372-95aa65adc9b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55467f4b-8437-43a3-b6d9-1bc2a13b4c11 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e8bc65e-8048-4073-8e45-570330603000 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:823b11cb-d873-4017-a861-d22d2c5a8a49 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34ec4989-6933-4237-ae1e-50a0cb90a2fe (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b310c6b-e035-4e44-9573-4001d58b2ad5 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0addf3f5-9bd5-4ef3-8c7f-52be20c16cf9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:393cd10e-133c-4d6b-b024-270eb82edbb3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca08d4aa-3de2-4a9d-9554-6288e5d36f29 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on Tacrolimus concentrations.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54fcc518-21d9-44a8-9e2c-87ebc2b3e2e6 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46ac55cf-d85e-4c34-bb33-f49e078c4a03 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e55495-10cc-4f6e-b866-1e7d6e45888b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:213f6047-f897-48a7-b78a-45d7124f2f16 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651bd506-96b0-43e5-a4dd-db03bf9154c9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e898ee90-faae-42a8-b652-be1c8730d856 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b601eaf-4f3a-4a8b-8cd8-1000defa9822 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:976f1b69-dd96-4815-b11b-839ce1c45633 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dc347e3-9bfd-4910-adb5-24e979208345 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2d2e3a1-f346-4245-b445-6dd44e371180 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b89e8a4-9f11-42e3-8e79-fe617e7c461f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d1c12a-bf4b-4467-93a0-ee8b892abea9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4caa20af-45a8-4365-9f06-1568afae61b1 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23b7b4d7-1431-e9f2-43ba-eabd169dc2dd (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4±1% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d502961-e9c0-4611-92bf-ce742a7b962c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1.0% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:875f4962-557e-4e12-ad7b-cb5fb6f2a65f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Fecal elimination accounted for 92.4 ± 1% and the elimination half-life based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 ± 11.6 hours based on tacrolimus concentrations.
    2. 31.9 ± 10.5 hours

      Numeric value
      31.9
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de2315b0-6344-43ac-9aea-3e3b68d828e7 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        The elimination half-life based on radioactivity was 31.9 ± 10.5 hours, whereas it was 48.4 ± 12.3 hours based on tacrolimus concentrations.
    3. 36 hours

      Numeric value
      36
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Food delayed the median T max from 2 hours in the fasted state to 4 hours in the fed state; however, the terminal half-life remained 36 hours regardless of dosing conditions.
  3. Projected row 1443

    Medicine slug
    tacrolimus
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    44
    Source count
    44
    Agreement rate
    1
    Recorded readings
    1. 99%

      Numeric value
      99
      Unit
      %
      Source records
      44

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 44 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61dee012-43af-0e9a-3843-9b9b91e022c4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e0584d-16d2-442b-86ce-e5e65239db0c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:759cf905-7406-4d1b-a1a8-10068cb11f04 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed7d1495-3585-409d-94f1-b3d2469d222c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f667de1-9dfa-4bd6-8ba0-15ee2d78873b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5‑50 ng/mL.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10ceb3bc-11cc-13e4-e063-6394a90acce4 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d03943-0655-44f6-b494-57bd1e336a34 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f21115e2-1d02-4bce-9c13-bf593a52a12f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd447ffa-9196-4c3c-accf-5adf29b84665 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f742224-618e-4f4c-bdec-7693be99c697 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3519febc-c9df-4559-b07a-92f8b0c7e770 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd9fea26-0236-d437-c7df-4b7636210875 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bf44a84-14fd-4f80-ad8a-99b1431d631f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27154d3a-eec5-4000-a4ff-bfbfe27eb806 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e6817a-9b1e-4f0f-e053-2a91aa0a3d15 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:450c3e32-6d91-4508-b064-49b293e86cec (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45af3eda-caaa-4478-9372-95aa65adc9b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55467f4b-8437-43a3-b6d9-1bc2a13b4c11 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e8bc65e-8048-4073-8e45-570330603000 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 ng/mL to 50 ng/mL.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:823b11cb-d873-4017-a861-d22d2c5a8a49 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34ec4989-6933-4237-ae1e-50a0cb90a2fe (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b310c6b-e035-4e44-9573-4001d58b2ad5 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0addf3f5-9bd5-4ef3-8c7f-52be20c16cf9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:393cd10e-133c-4d6b-b024-270eb82edbb3 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca08d4aa-3de2-4a9d-9554-6288e5d36f29 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of Tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54fcc518-21d9-44a8-9e2c-87ebc2b3e2e6 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46ac55cf-d85e-4c34-bb33-f49e078c4a03 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e55495-10cc-4f6e-b866-1e7d6e45888b (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:213f6047-f897-48a7-b78a-45d7124f2f16 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651bd506-96b0-43e5-a4dd-db03bf9154c9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e898ee90-faae-42a8-b652-be1c8730d856 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b601eaf-4f3a-4a8b-8cd8-1000defa9822 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:976f1b69-dd96-4815-b11b-839ce1c45633 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de2315b0-6344-43ac-9aea-3e3b68d828e7 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dc347e3-9bfd-4910-adb5-24e979208345 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2d2e3a1-f346-4245-b445-6dd44e371180 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b89e8a4-9f11-42e3-8e79-fe617e7c461f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 ng/mL to 50 ng/mL.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d1c12a-bf4b-4467-93a0-ee8b892abea9 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4caa20af-45a8-4365-9f06-1568afae61b1 (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23b7b4d7-1431-e9f2-43ba-eabd169dc2dd (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d502961-e9c0-4611-92bf-ce742a7b962c (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5–50 nanogram/mL.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:875f4962-557e-4e12-ad7b-cb5fb6f2a65f (opens source in a new tab)

        Tacrolimus label

        Version not recorded · Effective date not recorded

        Distribution The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL.
  4. Projected row 1444

    Medicine slug
    tadalafil
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    141
    Source count
    141
    Agreement rate
    0.886525
    Recorded readings
    1. 17.5 hours

      Numeric value
      17.5
      Unit
      hours
      Source records
      125

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 125 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36350106-98bc-41fc-bede-8be5e6f54a8a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3190ceb-fb3f-45f7-a12d-4c333edaadc6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:594acc15-a5bc-43b5-9659-a864b2c46eea (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31c05a53-7282-46d0-81bd-108defe6fb38 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a930511d-110e-4d2e-a4ca-df712f968b2d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a9cf85a-c17d-6890-e063-6394a90a93e9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:716c586d-e524-4f3e-ab1d-7ef9184169d9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09ad27a1-3908-4533-b84c-7a7fd3514101 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:761dc0f8-2f65-4615-ab49-a4bcffd40ce9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:741102c1-8809-44d4-9098-3dc8c0604764 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f317fe1e-d7c4-fb8b-e053-2a95a90a5445 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad288e9d-020a-43a0-9c07-320c5c3bbc1e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eedf3ad9-7d40-496d-b1a9-6200010c18e1 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351e28ca-3ae6-e535-e063-6394a90a9fb7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2e8821e-04c9-4812-8c9e-39340775cc6e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f295f164-78fb-4224-b319-9f20b7a453b5 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aba646fe-70c2-1abb-e053-2995a90aa16d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fd94914-0c9d-4268-8ed8-3c2690707a5d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfe43ab8-8721-4db8-8810-f0072cf8f4d3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30ae58ed-5b56-4513-8eb3-eb4f89b78f9d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f83ea2e-8ee8-ab6d-e053-2995a90a1e96 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a84c1eab-5934-4e5d-8bb2-0734d6adba6a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1580ab76-e229-4b8d-8c7b-82f39fecfebd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f3092f5a-b976-91ab-e053-2995a90a9b50 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ea24573-2d16-40d8-a46c-7b5fa8669e69 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3409762-3b2b-1cfc-e053-2995a90ab91b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fee8c2be-ccfa-4c66-abed-5e232ec762ae (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c277890-3c5d-5fd5-e063-6394a90af15b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351de7c2-98bf-7c88-e063-6294a90ad811 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3892605-4eb1-4d6e-a675-f7f7d4302f38 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fa9d4fa-86c9-4791-b28b-78e8b9341cea (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:929e391e-b74b-4ccd-8690-16ffcece7a30 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf35291b-b05b-1182-e053-2995a90a8dee (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1840f16-a7ea-44bd-b091-5268990aedb2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abcb2cda-9b3f-45f6-ad5f-c2370b0dd114 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c680b37-d515-4fc2-83e6-411f1017e18c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ea7612b-b004-43ef-accc-34c8ec5146b8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa8d165b-0c7d-497a-b56a-7c62ebc0a5d2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a10d464a-6ea7-4e5a-befa-71eceacc5039 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca1d46e3-ad9b-48c7-bb7f-63ee678ccf7a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b539e862-d5d4-4989-a3dd-1eba66285d53 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17947ccd-6f0e-d4cd-e063-6294a90a108a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13a107ba-cbbd-7760-e063-6394a90a1ee8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a4666e1-4151-f540-e063-6394a90aed0b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2354c3e2-7b5f-4fdd-bbf2-7fa3c57686f8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5de70f00-00ac-4656-883e-d1e07d5f71d6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e236f83-14bf-4862-91fb-74d766aef6a9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd94158b-43fa-44fc-a858-0983770efa83 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3a58c17-f260-4125-abd1-27da00bb0719 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16f13179-7c87-aa6c-e063-6294a90a93eb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07567ae5-7345-4ab1-9b2c-c586c4da0427 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6847ad6-3b5b-47e5-a3b5-04dc3182d72b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52505a7a-e3dd-7c4e-e063-6294a90a1473 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a105ef9-7129-4ce1-bd8d-ae316bf348e2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:101f44e4-669c-4e3d-843a-a27157750f9c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0345b81b-f946-4dd6-b49d-2a2bdd4c49c9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9d71483-861b-465b-846b-d7bfd6cbac11 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1dd9d05-e9d3-49ea-aeda-047536a27037 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eae8756-5c7f-2545-e063-6294a90a6d52 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85ed0cbc-df84-44df-a9eb-f9587dbc21df (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48850075-ac57-abb7-e063-6394a90a7881 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2121cd9b-a2c0-4f19-a33d-939c6fb3826d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c835a34a-9bae-4d88-b951-1b78ab92f388 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05640a4d-afb7-42ae-a5bb-77dbc8412356 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:415bd983-86f3-4f38-917a-9805024f31cb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9e9a953-2802-4bb1-91a3-a29be347801e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac93704f-8e33-43ba-8b56-3d61092ff1d9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1c8feb4-a85a-4f39-8c44-bc9cd77226f4 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78b6659c-3a46-4998-9151-1a53afd83375 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2d163aa-1056-47dd-85aa-297800e6c772 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:828f0ee1-b9fc-4743-9394-fc086bcf5345 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa345972-40b4-415e-acb5-31b808a8d815 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185a3284-3a4f-44d3-9278-98581d33f95b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3ee8325-bcb2-43fd-e053-2a95a90a08c8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ea97208-5afc-4943-b35c-ea850203a794 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2ec257-06bc-4ca4-9cf3-d0f49980e374 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6e8c52f-4dc3-5d54-e053-2995a90a9358 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6caf3b55-9bf4-4355-9e25-8bf368943fdd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad14d63-42e7-493f-b56c-e02a4fd139f7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e899da81-a28e-4a7e-a0e6-ed6d557c0bcd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1dace1e7-c617-492f-bb0d-141bf4e673db (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0acad71-8ae3-2827-e053-2995a90a20b3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4d9851c-5c06-4532-bd82-16d92b60c28f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b75f746-866e-3a5b-e063-6294a90a5e02 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ad52dff-9fcd-041f-e063-6394a90afcef (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6213fd38-9580-4253-91d2-14c28a711c20 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc7596dd-42d3-af7c-e053-6294a90af01e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf353da9-31c6-66c2-e053-2995a90a3bb0 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34e4747-28be-4ae5-ac9a-a825083b6a9b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bcd8f8ab-81a2-4891-83db-24a0b0e25895 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89a33a41-0f01-4f29-8b2f-769d649fbdcb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0f728b6-2cc6-cb65-e053-2a95a90ab142 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:affacb88-4af3-4ce9-961b-7fc37b169e9a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c4108c6-9014-4bd8-e063-6294a90a88fa (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51f87c9b-038c-4793-b0d5-5359ae231074 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7b3937e-ff03-436a-a5d4-92a4771034b6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:add6afb8-d38c-47a2-8c35-d5940667bb0c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34684fe8-9bf3-47fd-e063-6394a90ac80f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:66e24ced-0008-40cb-b242-9d9add1f665c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:168a135b-1454-4def-9b03-c9a470bfcb5f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b96ae7f1-7d4a-a211-e053-2995a90ab6e2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:491cb72b-71f2-4df9-99f8-c02d93500103 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e4cdac1-42cc-4038-a86b-4890962ed806 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90f38460-62ad-492e-a3da-403d5a5a5d86 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e7f393-5cfc-45e5-b87d-9e8abc8e4355 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7dfb450b-4d39-40e7-b115-9a96023052a0 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion —The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff3c7dd3-2dcc-498c-a121-1e2aa62c7a97 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00cbc656-768d-4995-bb6d-a0d4b32a248c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bce03930-14c5-401f-ad17-06b7709983bc (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24b82a6a-1b7e-42e6-b29b-41d4ee4d525f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31f5dc06-50f8-47cf-e063-6294a90ad5fb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7976c4ec-ecc4-4a49-a4fe-f990aece2d3c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4348b7db-e5b2-4e87-8cdd-674797a18890 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa547e3d-455a-4926-9fd9-349930898502 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc14daa3-cae9-4751-9034-b0e9c18054b4 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:248a4705-1403-e94a-e063-6294a90a3544 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22b8a2e3-d1b8-f193-45fa-77cc62a1b941 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a73b0e6f-09fc-42d6-a678-1409ce746bd1 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion - The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cad2167-dbd1-4df8-b407-b270487d027b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        E xcr etion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a132af-d75e-2ca0-e053-2a95a90a332e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae801b15-0462-44af-99a4-affe3eed899a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78509a43-a907-4359-9022-f38c4f765880 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82dfea4c-9fe5-438a-917f-8f7d395ee8ca (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8def23c-55ea-4796-9735-dbcb25104835 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48892acb-43bb-a4d8-e063-6394a90a5d61 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Excretion — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects.
    2. 15 hours

      Numeric value
      15
      Unit
      hours
      Source records
      16

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 16 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0ecc7cf-20dd-485a-b4dd-1bbc587280a7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84cb16c8-30ab-49f2-a6df-ec3c97bf6284 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efa03afa-c412-4b31-bf26-7c3a6f7311af (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cec49f6c-71f1-4de7-b515-1612ae16e5db (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc0a6a03-5ef1-4507-b888-5b559653c3e9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93dd604f-8f38-4600-afe8-0fcc92fd2497 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88132351-7fee-47ef-8007-ef2777543299 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9489b635-385e-4a05-be02-df39fcafebe3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c1c2136-099f-6232-e063-6294a90a6975 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf6fc925-ad20-4ed0-9356-15d24afa8d0b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0afd0728-256a-293b-e063-6394a90a3c5f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination - Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fceb8aaf-b4eb-4004-8ca4-f004eac6b314 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a909b25-3772-403e-a5fe-e4a040293fb7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff61b237-be8e-461b-8114-78c52a8ad0ae (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61955171-ca57-e300-1983-9472a56ca976 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects.
  5. Projected row 1445

    Medicine slug
    tadalafil
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    141
    Source count
    141
    Agreement rate
    0.886525
    Recorded readings
    1. 63 L

      Numeric value
      63
      Unit
      L
      Source records
      125

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 125 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36350106-98bc-41fc-bede-8be5e6f54a8a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3190ceb-fb3f-45f7-a12d-4c333edaadc6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:594acc15-a5bc-43b5-9659-a864b2c46eea (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31c05a53-7282-46d0-81bd-108defe6fb38 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a930511d-110e-4d2e-a4ca-df712f968b2d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a9cf85a-c17d-6890-e063-6394a90a93e9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:716c586d-e524-4f3e-ab1d-7ef9184169d9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09ad27a1-3908-4533-b84c-7a7fd3514101 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:761dc0f8-2f65-4615-ab49-a4bcffd40ce9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:741102c1-8809-44d4-9098-3dc8c0604764 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f317fe1e-d7c4-fb8b-e053-2a95a90a5445 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad288e9d-020a-43a0-9c07-320c5c3bbc1e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eedf3ad9-7d40-496d-b1a9-6200010c18e1 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351e28ca-3ae6-e535-e063-6394a90a9fb7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2e8821e-04c9-4812-8c9e-39340775cc6e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f295f164-78fb-4224-b319-9f20b7a453b5 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aba646fe-70c2-1abb-e053-2995a90aa16d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fd94914-0c9d-4268-8ed8-3c2690707a5d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfe43ab8-8721-4db8-8810-f0072cf8f4d3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30ae58ed-5b56-4513-8eb3-eb4f89b78f9d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f83ea2e-8ee8-ab6d-e053-2995a90a1e96 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a84c1eab-5934-4e5d-8bb2-0734d6adba6a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1580ab76-e229-4b8d-8c7b-82f39fecfebd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f3092f5a-b976-91ab-e053-2995a90a9b50 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ea24573-2d16-40d8-a46c-7b5fa8669e69 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3409762-3b2b-1cfc-e053-2995a90ab91b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fee8c2be-ccfa-4c66-abed-5e232ec762ae (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c277890-3c5d-5fd5-e063-6394a90af15b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351de7c2-98bf-7c88-e063-6294a90ad811 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3892605-4eb1-4d6e-a675-f7f7d4302f38 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fa9d4fa-86c9-4791-b28b-78e8b9341cea (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:929e391e-b74b-4ccd-8690-16ffcece7a30 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf35291b-b05b-1182-e053-2995a90a8dee (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1840f16-a7ea-44bd-b091-5268990aedb2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abcb2cda-9b3f-45f6-ad5f-c2370b0dd114 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c680b37-d515-4fc2-83e6-411f1017e18c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ea7612b-b004-43ef-accc-34c8ec5146b8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa8d165b-0c7d-497a-b56a-7c62ebc0a5d2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a10d464a-6ea7-4e5a-befa-71eceacc5039 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca1d46e3-ad9b-48c7-bb7f-63ee678ccf7a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b539e862-d5d4-4989-a3dd-1eba66285d53 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17947ccd-6f0e-d4cd-e063-6294a90a108a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13a107ba-cbbd-7760-e063-6394a90a1ee8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a4666e1-4151-f540-e063-6394a90aed0b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2354c3e2-7b5f-4fdd-bbf2-7fa3c57686f8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5de70f00-00ac-4656-883e-d1e07d5f71d6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e236f83-14bf-4862-91fb-74d766aef6a9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd94158b-43fa-44fc-a858-0983770efa83 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3a58c17-f260-4125-abd1-27da00bb0719 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16f13179-7c87-aa6c-e063-6294a90a93eb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07567ae5-7345-4ab1-9b2c-c586c4da0427 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6847ad6-3b5b-47e5-a3b5-04dc3182d72b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52505a7a-e3dd-7c4e-e063-6294a90a1473 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a105ef9-7129-4ce1-bd8d-ae316bf348e2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:101f44e4-669c-4e3d-843a-a27157750f9c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0345b81b-f946-4dd6-b49d-2a2bdd4c49c9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9d71483-861b-465b-846b-d7bfd6cbac11 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1dd9d05-e9d3-49ea-aeda-047536a27037 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eae8756-5c7f-2545-e063-6294a90a6d52 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85ed0cbc-df84-44df-a9eb-f9587dbc21df (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48850075-ac57-abb7-e063-6394a90a7881 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2121cd9b-a2c0-4f19-a33d-939c6fb3826d (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c835a34a-9bae-4d88-b951-1b78ab92f388 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05640a4d-afb7-42ae-a5bb-77dbc8412356 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:415bd983-86f3-4f38-917a-9805024f31cb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9e9a953-2802-4bb1-91a3-a29be347801e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac93704f-8e33-43ba-8b56-3d61092ff1d9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1c8feb4-a85a-4f39-8c44-bc9cd77226f4 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78b6659c-3a46-4998-9151-1a53afd83375 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2d163aa-1056-47dd-85aa-297800e6c772 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:828f0ee1-b9fc-4743-9394-fc086bcf5345 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa345972-40b4-415e-acb5-31b808a8d815 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185a3284-3a4f-44d3-9278-98581d33f95b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3ee8325-bcb2-43fd-e053-2a95a90a08c8 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ea97208-5afc-4943-b35c-ea850203a794 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2ec257-06bc-4ca4-9cf3-d0f49980e374 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6e8c52f-4dc3-5d54-e053-2995a90a9358 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6caf3b55-9bf4-4355-9e25-8bf368943fdd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad14d63-42e7-493f-b56c-e02a4fd139f7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e899da81-a28e-4a7e-a0e6-ed6d557c0bcd (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1dace1e7-c617-492f-bb0d-141bf4e673db (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0acad71-8ae3-2827-e053-2995a90a20b3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4d9851c-5c06-4532-bd82-16d92b60c28f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b75f746-866e-3a5b-e063-6294a90a5e02 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ad52dff-9fcd-041f-e063-6394a90afcef (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6213fd38-9580-4253-91d2-14c28a711c20 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc7596dd-42d3-af7c-e053-6294a90af01e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf353da9-31c6-66c2-e053-2995a90a3bb0 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34e4747-28be-4ae5-ac9a-a825083b6a9b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bcd8f8ab-81a2-4891-83db-24a0b0e25895 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Figure Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89a33a41-0f01-4f29-8b2f-769d649fbdcb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0f728b6-2cc6-cb65-e053-2a95a90ab142 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:affacb88-4af3-4ce9-961b-7fc37b169e9a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c4108c6-9014-4bd8-e063-6294a90a88fa (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51f87c9b-038c-4793-b0d5-5359ae231074 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7b3937e-ff03-436a-a5d4-92a4771034b6 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:add6afb8-d38c-47a2-8c35-d5940667bb0c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34684fe8-9bf3-47fd-e063-6394a90ac80f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:66e24ced-0008-40cb-b242-9d9add1f665c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:168a135b-1454-4def-9b03-c9a470bfcb5f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b96ae7f1-7d4a-a211-e053-2995a90ab6e2 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:491cb72b-71f2-4df9-99f8-c02d93500103 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e4cdac1-42cc-4038-a86b-4890962ed806 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90f38460-62ad-492e-a3da-403d5a5a5d86 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e7f393-5cfc-45e5-b87d-9e8abc8e4355 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7dfb450b-4d39-40e7-b115-9a96023052a0 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution —The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff3c7dd3-2dcc-498c-a121-1e2aa62c7a97 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00cbc656-768d-4995-bb6d-a0d4b32a248c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bce03930-14c5-401f-ad17-06b7709983bc (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24b82a6a-1b7e-42e6-b29b-41d4ee4d525f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31f5dc06-50f8-47cf-e063-6294a90ad5fb (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7976c4ec-ecc4-4a49-a4fe-f990aece2d3c (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4348b7db-e5b2-4e87-8cdd-674797a18890 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa547e3d-455a-4926-9fd9-349930898502 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc14daa3-cae9-4751-9034-b0e9c18054b4 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:248a4705-1403-e94a-e063-6294a90a3544 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22b8a2e3-d1b8-f193-45fa-77cc62a1b941 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a73b0e6f-09fc-42d6-a678-1409ce746bd1 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cad2167-dbd1-4df8-b407-b270487d027b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a132af-d75e-2ca0-e053-2a95a90a332e (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae801b15-0462-44af-99a4-affe3eed899a (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78509a43-a907-4359-9022-f38c4f765880 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82dfea4c-9fe5-438a-917f-8f7d395ee8ca (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8def23c-55ea-4796-9735-dbcb25104835 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48892acb-43bb-a4d8-e063-6394a90a5d61 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues.
    2. 77 L

      Numeric value
      77
      Unit
      L
      Source records
      16

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 16 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0ecc7cf-20dd-485a-b4dd-1bbc587280a7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84cb16c8-30ab-49f2-a6df-ec3c97bf6284 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efa03afa-c412-4b31-bf26-7c3a6f7311af (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cec49f6c-71f1-4de7-b515-1612ae16e5db (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc0a6a03-5ef1-4507-b888-5b559653c3e9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93dd604f-8f38-4600-afe8-0fcc92fd2497 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88132351-7fee-47ef-8007-ef2777543299 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9489b635-385e-4a05-be02-df39fcafebe3 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c1c2136-099f-6232-e063-6294a90a6975 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf6fc925-ad20-4ed0-9356-15d24afa8d0b (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0afd0728-256a-293b-e063-6394a90a3c5f (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution - The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fceb8aaf-b4eb-4004-8ca4-f004eac6b314 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a909b25-3772-403e-a5fe-e4a040293fb7 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff61b237-be8e-461b-8114-78c52a8ad0ae (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61955171-ca57-e300-1983-9472a56ca976 (opens source in a new tab)

        Tadalafil label

        Version not recorded · Effective date not recorded

        Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues.
  6. Projected row 1446

    Medicine slug
    tafasitamab-cxix
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    2
    Source count
    2
    Agreement rate
    0.5
    Recorded readings
    1. 13.4 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e0a220b-517f-4c86-b581-ffbab493fb58 (opens source in a new tab)

        Tafasitamab-Cxix label

        Version not recorded · Effective date not recorded

        Elimination Tafasitamab-cxix estimated elimination half-life was 13.4 days (31.7%) with an apparent clearance of 0.44 L/day (29.2%).
    2. 17 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec13ac6b-bfde-4e84-907a-83bd69584d95 (opens source in a new tab)

        Tafasitamab-Cxix label

        Version not recorded · Effective date not recorded

        Elimination The clearance of tafasitamab-cxix was 0.41 L/day (CV: 32%) and terminal elimination half-life was 17 days (95% CI: 15, 18 days).
  7. Projected row 1447

    Medicine slug
    tafasitamab-cxix
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    2
    Source count
    2
    Agreement rate
    0.5
    Recorded readings
    1. 7.11 L

      Numeric value
      7.11
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e0a220b-517f-4c86-b581-ffbab493fb58 (opens source in a new tab)

        Tafasitamab-Cxix label

        Version not recorded · Effective date not recorded

        C max (mcg/mL) C trough (mcg/mL) End of weekly dosing (end of Cycle 3) (N = 367) 315 (30.3%) 489 (22.8%) 226 (38.5%) Steady state Steady state values are approximated at Cycle 6 with every 2-week dosing (N = 285) 185 (32.5%) 375 (20.8%) 112 (44.8%) Distribution Tafasitamab-cxix steady state total volume of distribution was 7.11 L (29.7%).
    2. 9.3 L

      Numeric value
      9.3
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec13ac6b-bfde-4e84-907a-83bd69584d95 (opens source in a new tab)

        Tafasitamab-Cxix label

        Version not recorded · Effective date not recorded

        Distribution The total volume of distribution for tafasitamab-cxix was 9.3 L (95% CI: 8.6, 10 L).
  8. Projected row 1448

    Medicine slug
    tafenoquine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    3
    Source count
    2
    Agreement rate
    0.5
    Recorded readings
    1. 15 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cf989d5-36f5-4561-a30b-9fcb9deb6b6a (opens source in a new tab)

        Tafenoquine label

        Version not recorded · Effective date not recorded

        The average terminal half-life is approximately 15 days.
    2. 16.5 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:299e49d8-470f-4779-a010-4a1ee0e0c6cd (opens source in a new tab)

        Tafenoquine label

        Version not recorded · Effective date not recorded

        The mean terminal half-life following administration of ARAKODA is approximately 16.5 days (range: 10.8 days to 27.3 days) in healthy adult subjects.
  9. Projected row 1449

    Medicine slug
    tafenoquine
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    3
    Source count
    2
    Agreement rate
    0.5
    Recorded readings
    1. 1,600 L

      Numeric value
      1,600
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cf989d5-36f5-4561-a30b-9fcb9deb6b6a (opens source in a new tab)

        Tafenoquine label

        Version not recorded · Effective date not recorded

        The apparent oral volume of distribution is ~1,600 L.
    2. 2470 L

      Numeric value
      2,470
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:299e49d8-470f-4779-a010-4a1ee0e0c6cd (opens source in a new tab)

        Tafenoquine label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of tafenoquine in healthy adult subjects is 2470 L [Inter-Individual Variability (IIV): 24.1 %].
  10. Projected row 1450

    Medicine slug
    talazoparib
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings
    1. 74%

      Numeric value
      74
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2423edd-6d24-495c-aec1-c2f457f08d9a (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        In vitro , protein binding of talazoparib is 74% and is independent of talazoparib concentration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6fd147f-a77e-4a0b-9280-e82ecc41b4be (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        In vitro , protein binding of talazoparib is 74% and is independent of talazoparib concentration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13839d4f-6acf-4ffb-a128-79df59319273 (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        In vitro , protein binding of talazoparib is 74% and is independent of talazoparib concentration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b653221e-971f-4452-92d4-797924f1ff59 (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        In vitro , protein binding of talazoparib is 74% and is independent of talazoparib concentration.

Access

Query or download the projection

GET /api/datasets/source-consensus?limit=10&offset=1440

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy